Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol.

Chau Hung LeeBalamurugan VellayappanMatthias TaupitzBernd HammPatrick Asbach

Published in: European radiology (2019)

• At equal injection rate and equimolar total dose, gadobutrol compared with gadoterate meglumine provides a significantly greater relative enhancement in DCE-MR imaging of BPH over the first 180 s. • There are no significant differences in SNRs, CNRs, and pharmacokinetic parameters between the two GBCAs.

Keyphrases

contrast enhanced
benign prostatic hyperplasia
magnetic resonance imaging
lower urinary tract symptoms
prostate cancer
computed tomography
magnetic resonance
ultrasound guided